← Eichor
Study identifier: NCT07369076 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

Condition: Amyotrophic Lateral Sclerosis (ALS)  ·  Sponsor: Nura Bio

PhasePhase 1/Phase 2
Planned participants80
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis. The questions this trial aims to answer in comparing NB-4746 to placebo are: * What adverse events associated with taking NB-4746 are reported during this trial? (An adverse event is any sign or symptom that participants have during a trial. Adverse events may or may not be caused by treatments in the trial.) * How does NB-4746 move into, through, and out of the body of the participants? * What is the change in the level of neurofilament light (NfL) in the participants' blood? (NfL is a marker used to measure the extent of damage to the nerve cells.) This trial has 2 parts. The trial doctors will start Part A before starting Part B of the trial. Participants have an option to enter the open label extension after completing Part A or Part B. Part A: Participants will be randomly placed into 1 of the 3 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a low dose to take by mouth twice daily for 1 month. Group 2: Participants will receive NB-4746 capsules at a high dose to take by mouth twice daily for 1 month. Group 3: Participants will receive placebo capsules to take twice daily for approximately 1 month. Part B: Participants will be randomly placed into 1 of the 2 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 …

This description comes directly from the study's public registry record.

Talk to the study team

Lahar Mehta, MD  ·  801-918-7637  ·  lmehta@nurabio.com

Always discuss trial participation with your own doctor first.

Locations (8)

Concord Repatriation General HospitalConcord, New South Wales, AustraliaRecruiting
Neuroscience Research AustraliaRandwick, New South Wales, AustraliaRecruiting
Royal Brisbane and Women's HospitalBrisbane, Queensland, AustraliaRecruiting
Flinders Medical CentreBedford Park, South Australia, AustraliaRecruiting
Calvery Health care BethlehemCaulfield South, Victoria, AustraliaRecruiting
Perron InstituteNedlands, Western Australia, AustraliaRecruiting
Stan Cassidy Center for RehabilitationFredericton, New Brunswick, CanadaRecruiting
Genge PartnersMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07369076